XBIO

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Xenetic Biosciences Inc

NASDAQ | XBIO

3.87

USD

$0.00

(

0.00%

)

At Close (As of Oct 21, 2025)

$9.59M

Market Cap

-

P/E Ratio

-2

EPS

$13.93

52 Week High

$2.20

52 Week Low

HEALTHCARE

Sector

XBIO Chart

Recent Chart
Price Action

XBIO Technicals

Tags:

XBIO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $2.5M
Total Revenue $2.5M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$4.2M
Selling General And Administrative $3.4M
Research And Development $3.3M
Operating Expenses $6.7M
Investment Income Net -
Net Interest Income $250K
Interest Income $250K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $153K
Income Before Tax -$4M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$4M
Comprehensive Income Net Of Tax -
Ebit -$4.4M
Ebitda -$4.2M
Net Income -$4M

Revenue & Profitability

Earnings Performance

XBIO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $6.9M
Total Current Assets $6.6M
Cash And Cash Equivalents At Carrying Value $6.2M
Cash And Short Term Investments $6.2M
Inventory -
Current Net Receivables -
Total Non Current Assets $314K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $422K
Other Non Current Assets -
Total Liabilities $894K
Total Current Liabilities $894K
Current Accounts Payable $284K
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $0
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $611K
Other Non Current Liabilities -
Total Shareholder Equity $6M
Treasury Stock -
Retained Earnings -$197M
Common Stock $1.5K
Common Stock Shares Outstanding $1.5M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$2.8M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing -
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$4M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $2.5M
Total Revenue $2.5M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$4.2M
Selling General And Administrative $3.4M
Research And Development $3.3M
Operating Expenses $6.7M
Investment Income Net -
Net Interest Income $250K
Interest Income $250K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $153K
Income Before Tax -$4M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$4M
Comprehensive Income Net Of Tax -
Ebit -$4.4M
Ebitda -$4.2M
Net Income -$4M

XBIO News

XBIO Profile

Xenetic Biosciences Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Xenetic Biosciences Inc. is a forward-thinking biopharmaceutical company located in Framingham, Massachusetts, specializing in the development of next-generation cancer therapies. Through its proprietary XCART platform, the company is pioneering customized chimeric antigen receptor T (CAR T) cell treatments that specifically target and destroy tumor neoantigens unique to individual patients. Committed to addressing critical unmet medical needs in oncology, Xenetic is poised to significantly enhance treatment outcomes, positioning itself as a leader in the field of personalized medicine.

BYND
+146.25%
$3.62
YDKG
+27.99%
$0.05
YYAI
-19.18%
$0.08
VHAI
0.00%
$0.00
F
+4.75%
$12.56
VSEE
+93.56%
$0.94
CGBS
-39.47%
$0.03
NERV
+140.97%
$6.41
RANI
+26.66%
$2.85
GDXD
+29.73%
$0.86
NVDA
-0.81%
$181.16
PLUG
-8.23%
$3.12
BITF
-9.83%
$4.49
ADAP
-17.62%
$0.04
BURU
-14.84%
$0.28
T
-0.26%
$26.03
AIRE
+61.36%
$0.72
NVTS
+16.64%
$17.10
RGTI
-7.64%
$40.00
HPE
+1.74%
$23.27
CAN
-4.87%
$1.95
BTG
-9.12%
$5.18
DNN
-6.99%
$2.72
INTC
+0.05%
$38.11
WBD
+10.97%
$20.32
BOF
+33.65%
$2.80
JOBY
-7.63%
$16.10
AXDX
-61.36%
$0.03
CLF
-17.27%
$13.38
DVLT
0.00%
$2.41
IBIO
+24.30%
$1.11
RIG
+0.45%
$3.30
GSIT
-16.26%
$10.86
TLRY
-5.73%
$1.48
RXRX
-8.53%
$6.11
SOFI
+0.24%
$28.75
ETHD
-0.53%
$3.73
ABEV
-2.42%
$2.21
TSLA
-1.07%
$442.60
RF
+1.22%
$24.35
ABAT
+38.55%
$6.72
AMZN
+2.56%
$222.03
GRAB
-1.23%
$5.60
AMD
-1.05%
$238.03
GOOGL
-2.37%
$250.46
QUBT
-7.40%
$16.00
ACHR
-4.84%
$11.40
IONZ
+1.48%
$4.11
GM
+14.84%
$66.61
SOUN
-4.35%
$18.23
RR
+1.25%
$5.63
LAES
-8.46%
$5.93
VALE
-1.22%
$11.26
BTBT
-8.29%
$3.87
NEHC
+23.95%
$5.64
PFE
+0.64%
$24.85
QBTS
-6.36%
$32.21
IREN
-6.79%
$55.19
DCGO
+24.16%
$1.49
RMBL
+60.50%
$3.21
HAL
+11.53%
$25.23
MARA
-3.18%
$20.07
BBD
-2.21%
$3.30
AAL
+1.47%
$12.35
ADD
-25.47%
$0.05
GPUS
-7.57%
$0.36
DFLI
-3.96%
$1.21
AAPL
+0.38%
$263.26
CLSK
-7.62%
$18.84
NIO
-3.68%
$6.80
SRM
+53.27%
$10.30
CIFR
-9.21%
$18.07
BMNR
-3.45%
$51.94
KO
+4.10%
$71.25
ORCL
-4.85%
$277.18
SNAP
+1.68%
$7.86
PBR
-1.06%
$11.56
AMC
+3.61%
$2.87
NOK
-1.92%
$5.60
SMR
-13.23%
$38.36
HBAN
+0.63%
$15.94
VZ
-1.23%
$40.29
HIMS
-3.89%
$49.36
CUTR
-10.19%
$0.09
ONDS
-7.46%
$7.19
GGB
-1.17%
$3.37
WLGS
-5.57%
$0.04
PM
-3.78%
$152.08
CJET
-20.45%
$0.08
RIVN
+0.91%
$13.20
PLTR
-0.04%
$181.51
GOOG
-2.20%
$251.34
EPWK
-8.71%
$0.07
ETWO
0.00%
$3.30
APLD
-9.35%
$32.54
IONQ
-0.71%
$59.51
BULL
-2.96%
$11.14
RGTZ
+15.11%
$15.61
WTO
+2.93%
$0.06
MSN
+70.10%
$0.81
BYND
+146.25%
$3.62
YDKG
+27.99%
$0.05
YYAI
-19.18%
$0.08
VHAI
0.00%
$0.00
F
+4.75%
$12.56
VSEE
+93.56%
$0.94
CGBS
-39.47%
$0.03
NERV
+140.97%
$6.41
RANI
+26.66%
$2.85
GDXD
+29.73%
$0.86
NVDA
-0.81%
$181.16
PLUG
-8.23%
$3.12
BITF
-9.83%
$4.49
ADAP
-17.62%
$0.04
BURU
-14.84%
$0.28
T
-0.26%
$26.03
AIRE
+61.36%
$0.72
NVTS
+16.64%
$17.10
RGTI
-7.64%
$40.00
HPE
+1.74%
$23.27
CAN
-4.87%
$1.95
BTG
-9.12%
$5.18
DNN
-6.99%
$2.72
INTC
+0.05%
$38.11
WBD
+10.97%
$20.32
BOF
+33.65%
$2.80
JOBY
-7.63%
$16.10
AXDX
-61.36%
$0.03
CLF
-17.27%
$13.38
DVLT
0.00%
$2.41
IBIO
+24.30%
$1.11
RIG
+0.45%
$3.30
GSIT
-16.26%
$10.86
TLRY
-5.73%
$1.48
RXRX
-8.53%
$6.11
SOFI
+0.24%
$28.75
ETHD
-0.53%
$3.73
ABEV
-2.42%
$2.21
TSLA
-1.07%
$442.60
RF
+1.22%
$24.35
ABAT
+38.55%
$6.72
AMZN
+2.56%
$222.03
GRAB
-1.23%
$5.60
AMD
-1.05%
$238.03
GOOGL
-2.37%
$250.46
QUBT
-7.40%
$16.00
ACHR
-4.84%
$11.40
IONZ
+1.48%
$4.11
GM
+14.84%
$66.61
SOUN
-4.35%
$18.23
RR
+1.25%
$5.63
LAES
-8.46%
$5.93
VALE
-1.22%
$11.26
BTBT
-8.29%
$3.87
NEHC
+23.95%
$5.64
PFE
+0.64%
$24.85
QBTS
-6.36%
$32.21
IREN
-6.79%
$55.19
DCGO
+24.16%
$1.49
RMBL
+60.50%
$3.21
HAL
+11.53%
$25.23
MARA
-3.18%
$20.07
BBD
-2.21%
$3.30
AAL
+1.47%
$12.35
ADD
-25.47%
$0.05
GPUS
-7.57%
$0.36
DFLI
-3.96%
$1.21
AAPL
+0.38%
$263.26
CLSK
-7.62%
$18.84
NIO
-3.68%
$6.80
SRM
+53.27%
$10.30
CIFR
-9.21%
$18.07
BMNR
-3.45%
$51.94
KO
+4.10%
$71.25
ORCL
-4.85%
$277.18
SNAP
+1.68%
$7.86
PBR
-1.06%
$11.56
AMC
+3.61%
$2.87
NOK
-1.92%
$5.60
SMR
-13.23%
$38.36
HBAN
+0.63%
$15.94
VZ
-1.23%
$40.29
HIMS
-3.89%
$49.36
CUTR
-10.19%
$0.09
ONDS
-7.46%
$7.19
GGB
-1.17%
$3.37
WLGS
-5.57%
$0.04
PM
-3.78%
$152.08
CJET
-20.45%
$0.08
RIVN
+0.91%
$13.20
PLTR
-0.04%
$181.51
GOOG
-2.20%
$251.34
EPWK
-8.71%
$0.07
ETWO
0.00%
$3.30
APLD
-9.35%
$32.54
IONQ
-0.71%
$59.51
BULL
-2.96%
$11.14
RGTZ
+15.11%
$15.61
WTO
+2.93%
$0.06
MSN
+70.10%
$0.81
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.